{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T10:28:05Z","timestamp":1779186485314,"version":"3.51.4"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Patients with chronic myeloid leukemia (CML) show resistance to tyrosine kinase inhibitors (TKIs) targeting ABL1 due to the emergence of BCR::ABL1 mutants, especially compound mutants during the treatment, which brings great challenges to clinical practice. Combination therapy is an effective strategy for drug resistance. GMB-475, a proteolysis targeting chimera (PROTAC) targeting the myristoyl pocket of ABL1 in an allosteric manner, degrades the BCR::ABL1 through the ubiquitin\u2013proteasome pathway. In this study, we combined GMB-475 with orthosteric TKIs targeting ABL1 to overcome resistance. We constructed Ba\/F3 cells carrying BCR::ABL1 mutants by gene cloning technology and compared the effects of combination therapy with those of monotherapy on the biological characteristics and signaling pathways in CML cells. We found that the effects of ABL1 inhibitors, including imatinib, dasatinib, ponatinib, and ABL001, on growth inhibition and promoting apoptosis of Ba\/F3 cells with BCR::ABL1 mutants, especially compound mutants, were weakened. GMB-475 combined with TKIs, especially dasatinib, synergistically inhibited growth, promoted apoptosis, and blocked the cell cycle of Ba\/F3 cells carrying BCR::ABL1 mutants and synergistically blocked multiple molecules in the JAK-STAT pathway. In conclusion, dasatinib enhanced the antitumor effect of GMB-475; that is, the combination of PROTAC targeting ABL1 in an allosteric manner and orthosteric TKIs, especially dasatinib, provides a novel idea for the treatment of CML patients with BCR::ABL1 mutants in clinical practice.<\/jats:p>","DOI":"10.3389\/fphar.2022.931772","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T10:54:31Z","timestamp":1664794471000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants"],"prefix":"10.3389","volume":"13","author":[{"given":"Wu","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianfeng","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1002\/ajh.25939","article-title":"Phase I\/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia","volume":"95","author":"Abaza","year":"2020","journal-title":"Am. J. Hematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s12032-019-1253-5","article-title":"Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia.","volume":"36","author":"Alves","year":"2019","journal-title":"Med. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/13543784.2021.1941863","article-title":"Asciminib: An investigational agent for the treatment of chronic myeloid leukemia","volume":"30","author":"Breccia","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S ibrutinib-resistance mutation in bruton's tyrosine kinase using PROTAC-mediated degradation.","volume":"57","author":"Buhimschi","year":"2018","journal-title":"BIOCHEMISTRY"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","article-title":"Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein Degradation.Research support","volume":"79","author":"Burslem","year":"2019","journal-title":"Cancer Res.CANCER Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"642005","DOI":"10.3389\/fonc.2021.642005","article-title":"Dosing strategies for improving the risk-benefit profile of ponatinib in patients with chronic myeloid leukemia in chronic phase.","volume":"11","author":"Castagnetti","year":"2021","journal-title":"Front. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"444","DOI":"10.2741\/4901","article-title":"Crosstalk between CML cells with HUVECS and BMSCs through CML derived exosomes","volume":"26","author":"Cetin","year":"2021","journal-title":"Front. Biosci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/10428194.2020.1849679","article-title":"The regulation of bcr-abl in hypoxia is through the mTOR pathway","volume":"62","author":"Clapper","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"B9","doi-asserted-by":"publisher","first-page":"E5956","DOI":"10.3390\/molecules25245956","article-title":"The potential of proteolytic chimeras as pharmacological tools and therapeutic agents","volume":"25","author":"Coll-Mart\u00ednez","year":"2020","journal-title":"Molecules"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00277-021-04507-x","article-title":"Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.","volume":"100","author":"Devos","year":"2021","journal-title":"Ann. Hematol."},{"key":"B11","volume-title":"Chronic myelogenous leukemia","author":"Eden","year":"2021"},{"key":"B12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants.Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. [journal article; research support","volume":"36","author":"Eide","year":"2019","journal-title":"CANCER Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1016\/j.clinthera.2019.10.009","article-title":"Utility of therapeutic drug monitoring of imatinib, nilotinib, and dasatinib in chronic myeloid leukemia: A systematic review and meta-analysis","volume":"41","author":"Garc\u00eda-Ferrer","year":"2019","journal-title":"Clin. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1002\/anie.202012330","article-title":"RNA-PROTACs: Degraders of RNA-binding proteins.","volume":"60","author":"Ghidini","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B15","first-page":"4470","article-title":"Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1T315I-compound mutations.","volume":"11","author":"Gleixner","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1172\/JCI86249","article-title":"Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.","volume":"126","author":"Guignabert","year":"2016","journal-title":"J. Clin. Invest."},{"key":"B17","volume-title":"Genetics, Philadelphia Chromosome","author":"Haider","year":"2021"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/leu.2016.121","article-title":"Safety and efficacy of the combination of pegylated interferon-\u03b12b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients.","volume":"30","author":"Hjorth-Hansen","year":"2016","journal-title":"LEUKEMIA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1021\/acs.jmedchem.8b01572","article-title":"Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER).","volume":"62","author":"Hu","year":"2019","journal-title":"J. Med. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1177\/2472555220965528","article-title":"E3 ligase ligands for PROTACs: How they were found and how to discover new ones.","volume":"26","author":"Ishida","year":"2021","journal-title":"SLAS Discov."},{"key":"B21","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1021\/acschembio.7b00985","article-title":"Development of stabilized peptide-based PROTACs against estrogen receptor \u03b1.","volume":"13","author":"Jiang","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1158\/1535-7163.MCT-20-0069","article-title":"Allosteric inhibition of ABL kinases: Therapeutic potential in Cancer.Review]","volume":"19","author":"Jones","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.11406\/rinketsu.62.47","article-title":"[Successful treatment with ponatinib in combination with hyper-CVAD for chronic myeloid leukemia in the lymphoid blastic phase]","volume":"62","author":"Kakiuchi","year":"2021","journal-title":"Rinsho. Ketsueki."},{"key":"B24","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1177\/2472555221991104","article-title":"Small-molecule degraders beyond PROTACs-challenges and opportunities.","volume":"26","author":"Kastl","year":"2021","journal-title":"SLAS Discov."},{"key":"B25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: Frequency and clonal relationships.","volume":"121","author":"Khorashad","year":"2013","journal-title":"BLOOD"},{"key":"B26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/cas.14698","article-title":"AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR-ABL protein in CML cells.","volume":"112","author":"Koyama","year":"2021","journal-title":"Cancer Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1158\/1535-7163.MCT-20-0417","article-title":"Effects of MTX-23, a novel PROTAC of androgen receptor splice variant-7 and androgen receptor, on CRPC resistant to second-line antiandrogen therapy.","volume":"20","author":"Lee","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41467-020-20259-0","article-title":"Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem\/progenitor cells in chronic myelogenous leukemia.Research Support, Non-U.S. Gov't]","volume":"12","author":"Lei","year":"2021","journal-title":"Nat. Commun.Nature Commun."},{"key":"B29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejmech.2019.03.058","article-title":"Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).","volume":"172","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/cbdd.13801","article-title":"Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation.","volume":"97","author":"Liu","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"B31","doi-asserted-by":"publisher","first-page":"112993","DOI":"10.1016\/j.ejmech.2020.112993","article-title":"PROTACs to address the challenges facing small molecule inhibitors.","volume":"210","author":"Mart\u00edn-Acosta","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00277-020-04357-z","article-title":"Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K","volume":"100","author":"Mian","year":"2021","journal-title":"Ann. Hematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.16733","article-title":"Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: The UK TARGET CML study.","volume":"192","author":"Milojkovic","year":"2021","journal-title":"Br. J. Haematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1248\/bpb.b15-00103","article-title":"Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia","volume":"38","author":"Miura","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"B35","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s12185-021-03127-5","article-title":"Current status and novel strategy of CML","volume":"113","author":"Morita","year":"2021","journal-title":"Int. J. Hematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.2174\/0929867327666200312112412","article-title":"Recent advances in the design and development of anticancer molecules based on PROTAC technology.","volume":"28","author":"Mukhamejanova","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"106337","DOI":"10.1016\/j.leukres.2020.106337","article-title":"Novel therapeutic approaches in chronic myeloid leukemia","volume":"91","author":"\u00d6zg\u00fcr","year":"2020","journal-title":"Leuk. Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"B39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs) - past, present and future.","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today. Technol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1158\/2159-8290.CD-NB2020-054","article-title":"Proof-of-Concept with PROTACs in prostate cancer","volume":"10","year":"2020","journal-title":"Cancer Discov."},{"key":"B41","doi-asserted-by":"publisher","first-page":"692574","DOI":"10.3389\/fphar.2021.692574","article-title":"Protac: An effective targeted protein degradation strategy for cancer therapy.","volume":"12","author":"Qi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.2174\/0929867328666211110101018","article-title":"Overview of PROTACs targeting the estrogen receptor: Achievements for biological and drug discovery","volume":"29","author":"Qin","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"B43","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2174\/138920101405131111103750","article-title":"Allosteric inhibitors of bcr-abl: Towards novel myristate-pocket binders.","volume":"14","author":"Radi","year":"2013","journal-title":"Curr. Pharm. Biotechnol."},{"key":"B44","first-page":"2169","article-title":"Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors","volume":"26","author":"Radujkovic","year":"2006","journal-title":"Anticancer Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"101194","DOI":"10.1016\/j.beha.2020.101194","article-title":"Cml - not only BCR-ABL1 matters","volume":"33","author":"Rinke","year":"2020","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/cvr\/cvz006","article-title":"Ponatinib-induced cardiotoxicity: Delineating the signalling mechanisms and potential rescue strategies","volume":"115","author":"Singh","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12032-021-01462-5","article-title":"Combating TKI resistance in CML by inhibiting the PI3K\/Akt\/mTOR pathway in combination with TKIs: A review","volume":"38","author":"Singh","year":"2021","journal-title":"Med. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/MOH.0000000000000403","article-title":"Resistance in chronic myeloid leukemia: Definitions and novel therapeutic agents.","volume":"25","author":"Talati","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.","volume":"543","author":"Wylie","year":"2017","journal-title":"NATURE"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.4155\/fmc-2019-0159","article-title":"Triazol: A privileged scaffold for proteolysis targeting chimeras","volume":"11","author":"Xia","year":"2019","journal-title":"Future Med. Chem."},{"key":"B52","doi-asserted-by":"publisher","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"113150","DOI":"10.1016\/j.ejmech.2020.113150","article-title":"Discovery of a PROTAC targeting ALK with in\u00a0vivo activity","volume":"212","author":"Yan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"B54","doi-asserted-by":"publisher","first-page":"112981","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"B55","doi-asserted-by":"publisher","first-page":"113820","DOI":"10.1016\/j.ejmech.2021.113820","article-title":"Discovery of novel BTK PROTACs for B-Cell lymphomas","volume":"225","author":"Zhao","year":"2021","journal-title":"Eur. J. Med. Chem."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.931772\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T10:54:40Z","timestamp":1664794480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.931772\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":55,"alternative-id":["10.3389\/fphar.2022.931772"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.931772","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]},"article-number":"931772"}}